Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma

PHASE2CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

July 31, 2001

Primary Completion Date

August 31, 2004

Study Completion Date

May 31, 2008

Conditions
Malignant Mesothelioma
Interventions
DRUG

epirubicin hydrochloride

DRUG

gemcitabine hydrochloride

Trial Locations (24)

29303

CCOP - Upstate Carolina, Spartanburg

32224

Mayo Clinic - Jacksonville, Jacksonville

36607

MBCCOP - Gulf Coast, Mobile

48106

CCOP - Michigan Cancer Research Consortium, Ann Arbor

54301

CCOP - St. Vincent Hospital Cancer Center, Green Bay, Green Bay

55416

CCOP - Metro-Minnesota, Saint Louis Park

55805

CCOP - Duluth, Duluth

55905

Mayo Clinic Cancer Center, Rochester

56303

Coborn Cancer Center, Saint Cloud

57104

CCOP - Sioux Community Cancer Consortium, Sioux Falls

57709

Rapid City Regional Hospital, Rapid City

58122

CCOP - Merit Care Hospital, Fargo

61602

CCOP - Illinois Oncology Research Association, Peoria

61801

CCOP - Carle Cancer Center, Urbana

68106

CCOP - Missouri Valley Cancer Consortium, Omaha

70121

CCOP - Ochsner, New Orleans

85259-5404

CCOP - Mayo Clinic Scottsdale Oncology Program, Scottsdale

52403-1206

CCOP - Cedar Rapids Oncology Project, Cedar Rapids

50309-1016

CCOP - Iowa Oncology Research Association, Des Moines

51101-1733

Siouxland Hematology-Oncology, Sioux City

67214-3882

CCOP - Wichita, Wichita

58501-5505

Medcenter One Health System, Bismarck

43623-3456

CCOP - Toledo Community Hospital, Toledo

17822-2001

CCOP - Geisinger Clinic and Medical Center, Danville

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Alliance for Clinical Trials in Oncology

OTHER

NCT00017186 - Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma | Biotech Hunter | Biotech Hunter